FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801561664> ?p ?o ?g. }

• W2801561664 endingPage "79" @default.
• W2801561664 startingPage "71" @default.
• W2801561664 abstract "Objective Optimal targeted treatment in rheumatoid arthritis requires early identification of failure to respond. This post hoc analysis explored the relationship between early disease activity changes and the achievement of low disease activity ( LDA ) and remission targets with tofacitinib. Methods Data were from 2 randomized, double‐blind, phase III studies. In the ORAL Start trial, methotrexate ( MTX )–naive patients received tofacitinib 5 or 10 mg twice daily, or MTX , for 24 months. In the placebo‐controlled ORAL Standard trial, MTX inadequate responder patients received tofacitinib 5 or 10 mg twice daily or adalimumab 40 mg every 2 weeks, with MTX , for 12 months. Probabilities of achieving LDA (using a Clinical Disease Activity Index [ CDAI ] score ≤10 or the 4‐component Disease Activity Score in 28 joints using the erythrocyte sedimentation rate [ DAS 28‐ ESR ] ≤3.2) at months 6 and 12 were calculated, given failure to achieve threshold improvement from baseline (change in CDAI ≥6 or DAS 28‐ ESR ≥1.2) at month 1 or 3. Results In ORAL Start, 7.2% and 5.4% of patients receiving tofacitinib 5 and 10 mg twice daily, respectively, failed to show improvement in the CDAI ≥6 at month 3; of those who failed, 3.8% and 28.6%, respectively, achieved month 6 CDAI ‐defined LDA . In ORAL Standard, 18.8% and 17.5% of patients receiving tofacitinib 5 and 10 mg twice daily, respectively, failed to improve CDAI ≥6 at month 3; of those who failed, 0% and 2.9%, respectively, achieved month 6 CDAI ‐defined LDA . Findings were similar when considering improvements at month 1 or DAS 28‐ ESR thresholds. Conclusion In patients with an inadequate response to MTX , lack of response to tofacitinib after 1 or 3 months predicted a low probability of achieving LDA at month 6. Lack of an early response may be considered when deciding whether to continue treatment with tofacitinib." @default.
• W2801561664 created "2018-05-17" @default.
• W2801561664 creator A5000141404 @default.
• W2801561664 creator A5012009272 @default.
• W2801561664 creator A5017734958 @default.
• W2801561664 creator A5024958150 @default.
• W2801561664 creator A5029796262 @default.
• W2801561664 creator A5061868722 @default.
• W2801561664 creator A5080646462 @default.
• W2801561664 creator A5090182951 @default.
• W2801561664 date "2018-12-27" @default.
• W2801561664 modified "2023-10-09" @default.
• W2801561664 title "Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6" @default.
• W2801561664 cites W1974321634 @default.
• W2801561664 cites W1990105300 @default.
• W2801561664 cites W2014330392 @default.
• W2801561664 cites W2035320881 @default.
• W2801561664 cites W2038593306 @default.
• W2801561664 cites W2038992287 @default.
• W2801561664 cites W2046744512 @default.
• W2801561664 cites W2061900452 @default.
• W2801561664 cites W2069302785 @default.
• W2801561664 cites W2101217991 @default.
• W2801561664 cites W2119950842 @default.
• W2801561664 cites W2120393706 @default.
• W2801561664 cites W2126525702 @default.
• W2801561664 cites W2129948300 @default.
• W2801561664 cites W2142004396 @default.
• W2801561664 cites W2149447280 @default.
• W2801561664 cites W2152097701 @default.
• W2801561664 cites W2152348310 @default.
• W2801561664 cites W2153414586 @default.
• W2801561664 cites W2164858045 @default.
• W2801561664 cites W2169532722 @default.
• W2801561664 cites W2265836205 @default.
• W2801561664 cites W2509918787 @default.
• W2801561664 cites W2534106563 @default.
• W2801561664 cites W2560858281 @default.
• W2801561664 cites W2581513023 @default.
• W2801561664 cites W2592808921 @default.
• W2801561664 cites W2763284518 @default.
• W2801561664 doi "https://doi.org/10.1002/acr.23585" @default.
• W2801561664 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6590136" @default.
• W2801561664 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29696833" @default.
• W2801561664 hasPublicationYear "2018" @default.
• W2801561664 type Work @default.
• W2801561664 sameAs 2801561664 @default.
• W2801561664 citedByCount "5" @default.
• W2801561664 countsByYear W28015616642020 @default.
• W2801561664 countsByYear W28015616642022 @default.
• W2801561664 countsByYear W28015616642023 @default.
• W2801561664 crossrefType "journal-article" @default.
• W2801561664 hasAuthorship W2801561664A5000141404 @default.
• W2801561664 hasAuthorship W2801561664A5012009272 @default.
• W2801561664 hasAuthorship W2801561664A5017734958 @default.
• W2801561664 hasAuthorship W2801561664A5024958150 @default.
• W2801561664 hasAuthorship W2801561664A5029796262 @default.
• W2801561664 hasAuthorship W2801561664A5061868722 @default.
• W2801561664 hasAuthorship W2801561664A5080646462 @default.
• W2801561664 hasAuthorship W2801561664A5090182951 @default.
• W2801561664 hasBestOaLocation W28015616641 @default.
• W2801561664 hasConcept C126322002 @default.
• W2801561664 hasConcept C141071460 @default.
• W2801561664 hasConcept C142724271 @default.
• W2801561664 hasConcept C168563851 @default.
• W2801561664 hasConcept C204787440 @default.
• W2801561664 hasConcept C27081682 @default.
• W2801561664 hasConcept C2776233030 @default.
• W2801561664 hasConcept C2777575956 @default.
• W2801561664 hasConcept C2778143017 @default.
• W2801561664 hasConcept C2778886723 @default.
• W2801561664 hasConcept C2780132546 @default.
• W2801561664 hasConcept C2781059491 @default.
• W2801561664 hasConcept C535046627 @default.
• W2801561664 hasConcept C67761136 @default.
• W2801561664 hasConcept C71924100 @default.
• W2801561664 hasConcept C90924648 @default.
• W2801561664 hasConceptScore W2801561664C126322002 @default.
• W2801561664 hasConceptScore W2801561664C141071460 @default.
• W2801561664 hasConceptScore W2801561664C142724271 @default.
• W2801561664 hasConceptScore W2801561664C168563851 @default.
• W2801561664 hasConceptScore W2801561664C204787440 @default.
• W2801561664 hasConceptScore W2801561664C27081682 @default.
• W2801561664 hasConceptScore W2801561664C2776233030 @default.
• W2801561664 hasConceptScore W2801561664C2777575956 @default.
• W2801561664 hasConceptScore W2801561664C2778143017 @default.
• W2801561664 hasConceptScore W2801561664C2778886723 @default.
• W2801561664 hasConceptScore W2801561664C2780132546 @default.
• W2801561664 hasConceptScore W2801561664C2781059491 @default.
• W2801561664 hasConceptScore W2801561664C535046627 @default.
• W2801561664 hasConceptScore W2801561664C67761136 @default.
• W2801561664 hasConceptScore W2801561664C71924100 @default.
• W2801561664 hasConceptScore W2801561664C90924648 @default.
• W2801561664 hasFunder F4320307765 @default.
• W2801561664 hasIssue "1" @default.
• W2801561664 hasLocation W28015616641 @default.
• W2801561664 hasLocation W28015616642 @default.
• W2801561664 hasLocation W28015616643 @default.

• next